sur BIOSYNEX (EPA:ALBIO)
Launch of the capital increase by BIOSYNEX SA
BIOSYNEX SA has announced a capital increase with preferential subscription rights for a target amount of 7.99 million euros. This operation aims to strengthen its balance sheet and finance its working capital requirements. The unit subscription price is set at 1.00 euros, with a discount of 48% compared to the average price of 1.91 euros over the last 35 trading sessions.
The subscription period is scheduled from January 28 to February 7, 2025. The subscription commitment totals €6.0 million, supported mainly by Larry Abensur and a new investor for €4.6 million and €1.4 million respectively.
The Financial Markets Authority has granted Larry Abensur an exemption from the obligation to file a public takeover bid. This capital increase may result in a dilution of existing shares, as specified in the terms of the transaction.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BIOSYNEX